Cytosorbents Co. (NASDAQ:CTSO) Shares Acquired by Granahan Investment Management LLC

Granahan Investment Management LLC grew its position in Cytosorbents Co. (NASDAQ:CTSOGet Rating) by 10.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,215,928 shares of the medical research company’s stock after buying an additional 110,321 shares during the quarter. Granahan Investment Management LLC owned 2.79% of Cytosorbents worth $3,879,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of CTSO. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Cytosorbents in the fourth quarter valued at $199,000. Paradigm Financial Partners LLC acquired a new stake in shares of Cytosorbents in the fourth quarter valued at $159,000. GSA Capital Partners LLP acquired a new stake in shares of Cytosorbents in the fourth quarter valued at $54,000. Avenir Corp grew its stake in shares of Cytosorbents by 28.1% in the fourth quarter. Avenir Corp now owns 1,787,275 shares of the medical research company’s stock valued at $7,489,000 after buying an additional 391,890 shares in the last quarter. Finally, Winning Points Advisors LLC acquired a new position in Cytosorbents during the 1st quarter worth $218,000. 35.79% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Price Performance

CTSO opened at $1.73 on Friday. Cytosorbents Co. has a 12 month low of $1.65 and a 12 month high of $9.01. The stock has a market capitalization of $75.39 million, a price-to-earnings ratio of -2.11 and a beta of 0.42. The business has a fifty day moving average price of $2.05 and a 200 day moving average price of $2.41.

About Cytosorbents

(Get Rating)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.

See Also

Institutional Ownership by Quarter for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.